Re: retina vessel vasculitis

[Guest guest]

Jeanine,

L-carnosine (available OTC) and n-acetylcarnosine (patented, commercial

product)

have shown promise in topical application against cataracts.

Don't try to make carnosine eye drops yourself. Show the l-carnosine papers

to a compounding pharmacist.

Clin Experiment Ophthalmol. <javascript:AL_get(this, 'jour', 'Clin

Experiment Ophthalmol.');> 2007 Sep-Oct;35(7):664-71.[image: Click here to

read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3046 & itool=Abstrac\

tPlus-def & uid=17894689 & db=pubmed & url=http://www.blackwell-synergy.com/openurl?ge\

nre=article & sid=nlm:pubmed & issn=1442-6404 & date=2007 & volume=35 & issue=7 & spage=664>

Links <javascript:PopUpMenu2_Set(Menu17894689);>

Medical treatment of cataract. *Toh

T*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Toh%20T\

%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_Di\

scoveryPanel.Pubmed_RVAbstractPlus>,

*Morton

J*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Morton%\

20J%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed\

_DiscoveryPanel.Pubmed_RVAbstractPlus>,

*on

J*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22on%2\

0J%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_\

DiscoveryPanel.Pubmed_RVAbstractPlus>,

*Elder

MJ*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Elder%\

20MJ%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubme\

d_DiscoveryPanel.Pubmed_RVAbstractPlus>

..

Department of Ophthalmology, Christchurch Hospital, Christchurch, New

Zealand. ty_toh@...

The incidence of cataract continues to increase with the ageing of the

population. Surgical treatment with phacoemulsification and intraocular lens

implantation remains the only proven treatment. This, however, is associated

with significant cost and is not readily available especially in the

developing countries where the prevalence of cataract is the highest.

Medical treatment of cataract is therefore a highly desired alternative.

Since the last major review of medical treatment of cataract the search for

an anti-cataract agent has advanced on many fronts. Some anti-cataract

drugs, such as carnosine, have now reached clinical trials and showed

encouraging results that warrant further investigation. The discovery of an

effective medical treatment for cataract is likely to make global impact on

eye health. The aims of this paper are to review the literature on the drug

therapy of cataract and provide updates of the latest development.

PMID: 17894689 [PubMed - indexed for MEDLINE]

Yan Ke Xue Bao. <javascript:AL_get(this, 'jour', 'Yan Ke Xue Bao.');> 2006

Jun;22(2):85-8.Links <javascript:PopUpMenu2_Set(Menu17162883);>

[Preventive effect of carnosine on cataract development] [Article in

Chinese]

*Guo

Y*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Guo%20Y\

%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_Di\

scoveryPanel.Pubmed_RVAbstractPlus>,

*Yan

H*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Yan%20H\

%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_Di\

scoveryPanel.Pubmed_RVAbstractPlus>

..

Department of Ophthalmology, Tangdu Hospital, Fourth Military Medical

University, Xi'an 710038, China. yhongb@...

Carnosine (beta-alanyl-L-histidine) was the first and the simplest example

of active peptides (actually a dipeptide). The anti-ageing effect of

carnosine had been demonstrated in many studies in vivo and in vitro. More

recently,there were some studies verifying the effect of carnosine on

preventing cataract development.The molecular mechanisms are largely

undetermined. The effect of carnosine on delaying the cataract formation may

be through anti-glycation of protein, antioxidative impairment, protection

protein against cross-links and DNA damage. Further study of carnosine on

its biological features and the mechanisms of delaying the progression of

cataractogenesis may provide a new therapy for preventing cataract.

PMID: 17162883 [PubMed - indexed for MEDLINE]

* *Vet Ophthalmol. <javascript:AL_get(this, 'jour', 'Vet

Ophthalmol.');>2006 Sep-Oct;9(5):311-6.[image:

Click here to

read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3046 & itool=Abstrac\

tPlus-def & uid=16939459 & db=pubmed & url=http://www.blackwell-synergy.com/openurl?ge\

nre=article & sid=nlm:pubmed & issn=1463-5216 & date=2006 & volume=9 & issue=5 & spage=311>

Links <javascript:PopUpMenu2_Set(Menu16939459);>

The effect of a topical antioxidant formulation including N-acetyl carnosine

on canine cataract: a preliminary study. *

DL*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Willia\

ms%20DL%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pu\

bmed_DiscoveryPanel.Pubmed_RVAbstractPlus>,

*Munday

P*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Munday%\

20P%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed\

_DiscoveryPanel.Pubmed_RVAbstractPlus>

..

Department of Veterinary Medicine, University of Cambridge, Madingley Road,

Cambridge, CB3 OES, England, UK. doctordlwilliams@...

OBJECTIVE: To determine the efficacy of a topical antioxidant formulation

including N-acetyl carnosine in the treatment of canine cataract in a

preliminary nonplacebo, controlled, unmasked study. ANIMALS STUDIED: Thirty

dogs of varying breeds and ages with a spectrum of lens opacities ranging

from nuclear sclerosis to total mature cataract. METHODS: Dogs were treated

three times daily with topical 2% N-acetyl carnosine in a buffered vehicle

containing the antioxidants glutathione, cysteine ascorbate, L-taurine and

riboflavin (Ocluvet, Practivet, Phoenix, AZ, USA). Dogs were examined prior

to treatment and at 2, 4 and 8 weeks during treatment, by direct and

indirect ophthalmoscopy and slit-lamp biomicroscopy after pharmacologic

pupil dilation. Photographic documentation of lens opacity was achieved by

retroillumination photography, with three photographs taken at each

examination time-point. A lens opacification index (LOI), determined by

integration of the grayscale level of each pixel across the image, was

evaluated by computerized image analysis of digitized images. Alteration in

mean LOI was determined for each animal, having normalized the initial LOI.

RESULTS: Fifty-eight eyes of 30 dogs were evaluated, 22 with mature

cataract, 13 with immature cataract, 9 with cataract associated with other

intraocular disease such as uveitis and 14 with nuclear sclerosis alone. One

dog was unilaterally anophthalmic after previous enucleation and one had a

phthytic eye after previous uveitis-induced glaucoma. Image analysis showed

a reduction in mean LOI in all cataract groups (mean resolution in opacity

of 2.3 +/- 0.33% for all cataracts), although this was only statistically

significant in those eyes with immature cataract (mean resolution of opacity

4.5 +/- 0.33%) or nuclear sclerosis (mean decrease in opacity 5 +/- 0.37%).

Reduction in lens opacity was seen in eyes with mature cataract (0.5 +/-

0.4%) and in miscellaneous cataract associated with intraocular inflammation

(1.3 +/- 0.4%), but these changes were not statistically significant. Owner

evaluation of visual capability, however, suggested improvement in vision in

80% of cases by the end of the study. CONCLUSIONS: This study demonstrates

some marginal reduction in lens opacification in a substantial number of

cases of canine cataract with the use of a topical nutritional antioxidant

formulation including N-acetyl carnosine. Lens opacification was improved

with treatment in eyes with immature cataract or nuclear sclerosis while in

eyes with mature cataract or cataract with associated intraocular

inflammatory pathology less reduction was seen.

PMID: 16939459 [PubMed - indexed for MEDLINE]

Life Sci. <javascript:AL_get(this, 'jour', 'Life Sci.');> 2006 Apr

11;78(20):2343-57. Epub 2006 Jan 4.[image: Click here to

read]<http://www.ncbi.nlm.nih.gov/entrez/utils/fref.fcgi?PrId=3048 & itool=Abstrac\

tPlus-def & uid=16388826 & db=pubmed & url=http://linkinghub.elsevier.com/retrieve/pii\

/S0024-3205%2805%2901113-6>

Links <javascript:PopUpMenu2_Set(Menu16388826);>

Biological activities of the natural imidazole-containing peptidomimetics

n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care

products. *Babizhayev

MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\

ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\

Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>

..

Innovative Vision Products, Inc., 3511 Silverside Road, Suite 105, County of

New Castle, Delaware 19810, USA. markbabizhayev2004@...

Apart from genetically programmed cell aging, different external aggressors

related to oxidative stress and lipid peroxidation (LPO) can accelerate the

skin aging phenomenon. Oxidative stress associated with the formation of

lipid peroxides is suggested to contribute to pathological processes in

aging and systemic diseases known as the risk factors for cataract. Despite

the fact that L-carnosine-related peptidomimetics N-acetylcarnosine

(N-acetyl-beta-alanyl-L-histidine) (NAC) and carcinine

(beta-alanylhistamine) are metabolically related to L-carnosine and have

been demonstrated to occur in tissues of many vertebrates, including humans,

these compounds were shown resistant toward enzymatic hydrolysis. A series

of related biocompatible imidazole-containing peptidomimetics were

synthesized in order to confer resistance to enzymatic hydrolysis and ex

vivo improvement of protective antioxidative properties related to

L-carnosine. The included findings revealed a greater role of

N-acetylcarnosine (NAC) and carcinine ex vivo in the prolongation and

potentiation of physiological responses to the therapeutical and cosmetics

treatments with L-carnosine as antioxidant. 3-D molecular conformation

studies proposed the antioxidant activity of peptidomimetics (carcinine,

L-prolylhistamine, N-acetylcarnosine, L-carnosine) for metal ion binding,

quenching of a number free radicals, and binding of hydroperoxide or

aldehyde (including dialdehyde LPO products) in an imidazole-peroxide

adducts. NAC can act as a time release (carrier) stable version of

L-carnosine during application in ophthalmic pharmaceutical and cosmetics

formulations which include lubricants. Carcinine, L-prolylhistamine show

efficient deactivation of lipid hydroperoxides monitored by HPLC and

protection of membrane phospholipids and water soluble proteins from the

lipid peroxides-induced damages. This activity is superior over the

lipophilic antioxidant vitamin E. The biologically significant applications

of carnosine mimetics were patented by Dr. Babizhayev and the alliance

Groups (WO 2004/028536 A1; WO 94/19325; WO 95/12581; WO 2004/064866 A1).

PMID: 16388826 [PubMed - indexed for MEDLINE]

Biomed Khim. <javascript:AL_get(this, 'jour', 'Biomed Khim.');> 2005

Sep-Oct;51(5):481-4.Links <javascript:PopUpMenu2_Set(Menu16342664);>

[biological role of carnosine and its use in ophthalmology

(mini-review)] [Article

in Russian]

*Volkov

OV*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Volkov\

%20OV%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubm\

ed_DiscoveryPanel.Pubmed_RVAbstractPlus>

..

Carnosine (beta-alanyl-L-histidine) exhibits various biological effects

underlying its potential therapeutic use. In ophthalmology carnosine was

effective in treatment of corneal metabolic diseases, senile cataract. It

accelerated cornea reepithelization after photorephraction ceratoectomia.

PMID: 16342664 [PubMed - indexed for MEDLINE]

Drugs R D. <javascript:AL_get(this, 'jour', 'Drugs R D.');>2005;6(6):345-69.

Links <javascript:PopUpMenu2_Set(Menu16274259);>

Analysis of lipid peroxidation and electron microscopic survey of maturation

stages during human cataractogenesis: pharmacokinetic assay of Can-C

N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.

*Babizhayev

MA*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed & Cmd=Search & Term=%22Babizh\

ayev%20MA%22%5BAuthor%5D & itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.\

Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>

..

Innovative Vision Products Inc., County of New Castle, Delaware 19810, USA.

markbabizhayev@...

Morphological and biophysical techniques described in this study have shown

that membrane derangement occurs in human cataractous lenses. The data

suggest that these disruptions were globules, vacuoles, multilamellar

membranes and clusters of highly undulating membranes. Deleterious

structural damage of the lens fibre cell plasma membranes serve as the

primary light-scattering centres that cause the observed lens opacity.

Nuclear cataract, a major cause of loss of lens transparency in the aging

human, has been thought to be associated with oxidative damage, particularly

at the site of the nuclear plasma membrane. Phospholipid molecules modified

by oxygen accumulate in the lipid bilayer, change its geometry and impair

lipid-lipid and protein-lipid interactions in lenticular fibre membranes.

Lipid peroxidation (LPO) is a causative and pathogenic factor in cataract.

Increased concentrations of primary molecular LPO products (diene

conjugates, lipid hydroperoxides, oxy-derivatives of phospholipid fatty

acids) and end-fluorescent LPO products have been detected in the lipid

moieties of aqueous humour samples and human lenses obtained from patients

with senile and complicated cataracts as compared with normal donors. In the

present study, a rapid and simple high-performance liquid chromatographic

(HPLC) assay for determination of imidazole-containing dipeptides in the

aqueous humour of the eye was developed. The method was applied to determine

the pharmacokinetic parameters and the time-course of N-acetylcarnosine and

L-carnosine-related product in the eye, following a single dosage of topical

ocular administration of peptide. Utilising data from pharmacokinetic

studies and the specific purity of the N-acetylcarnosine (NAC) ingredient as

a source of the pharmacological principle L-carnosine, we have created an

ophthalmic time-release prodrug form including the US FDA-approved

carboxymethylcellulose lubricant and other essential ingredients (Can-C,

private label Nu-Eyes). This formulation increases the intraocular

absorption of L-carnosine in the aqueous humour and optimises its specific

antioxidant activity in vivo while reducing the toxic effects of lipid

peroxides on the crystalline lens. L-carnosine that enters the aqueous

humour can accumulate in the lens tissue for a reasonable period of time.

The presence of L-carnosine in transparent crystalline lenses during normal

aging was detected and its concentration in this case was about 25 microM.

At different stages of cataract development, the level of L-carnosine

drastically decreased, reaching about 5 microM in ripe human cataracts.

However, administration of pure L-carnosine (1% solution) to the rabbit eye

(instillation or subconjunctival injection) does not lead to accumulation of

this natural compound in the aqueous humour at the time level over 30

minutes at a concentration exceeding that in placebo-treated matched eyes,

and its effective concentration is exhausted more rapidly. Use of NAC

prodrug eye drops optimises the clinical effects of L-carnosine in the

treatment of ophthalmic disorders (such as prevention and reversal of

cataracts in human and animal [canine] eyes). The data provided predict a

clinical effect with NAC ophthalmic prodrug, and show that the magnitude and

duration of this effect are directly related to the bioavailability of

L-carnosine released from NAC in the aqueous humour of the anterior eye

segment. The ophthalmic NAC drug shows promise in the treatment of a range

of ophthalmic disorders that have a component of oxidative stress in their

pathogenesis (including cataract, glaucoma, dry eye, vitreous floaters,

inflammatory disorders, and corneal, retinal and systemic diseases [such as

diabetes mellitus and its ophthalmic complications]). There is a need for

further and better collaboration between Innovative Vision Products'

cataract control and ophthalmic services, improved education of people

affected by cataract, a commitment that N-acetylcarnosine eye drops will be

the preferred treatment before orthodox cataract surgery is attempted, and

consideration of outcomes and a possible role of the NAC drug cataract

treatment as source of referral for orthodox surgical, ophthalmic and

optometric services.

PMID: 16274259 [PubMed - indexed for MEDLINE]

etc, etc..

On Sat, Aug 9, 2008 at 12:16 AM, who <jeaninem660@...> wrote:

> you know, it really blows me away when I think about the mayo clinic

> diagniseing my cataracts on 2003 and saying that it was extremly rare

> for someone my age to get cataracts but they didn't even bother to

> think that they might want to look in my head to see if something was

> wrong. and than the many that followed that just said yep, you got

> cataracts we dont take it out until it gets bigger. didn't matter that

> I was telling other symptoms as in blurred vision, double vision+ and

> light sensitivity,problems judgeing distance and later foggyness over

> both eyes. well I'm no expert on reading these scans but it sure looks

> like there may have been some retina vessel vasculitis involved with

> the wirst part of my exposure that messed with my eyes and brain.

> even looks like maybe a little tissue damage there. grrr

>

>

>

[Guest guest]

Thank you Live, I'll check this out. ,u left eye is full so I don't srr

anyway around surgery, but stopping the process in the right eye would

be great.

--- In , LiveSimply <quackadillian@...>

wrote:

>

> Jeanine,

>

> L-carnosine (available OTC) and n-acetylcarnosine (patented,

commercial

> product)

> have shown promise in topical application against cataracts.

>

> Don't try to make carnosine eye drops yourself. Show the l-carnosine

papers

> to a compounding pharmacist.

>

[Guest guest]

Jeanine,

Your sight is very important. Give those papers to a compounding

pharmacist.. DON'T try to make somethng out of saline and carnosine

yourself..

Or better yet, buy the Can-C eye drops which, although obscenely expensive,

are a known quantity. After all, they have the patent.

The amount of carnosine used is VERY small (any more could damage your

eyes!) and a bottle of pure l-carnosine would probably last for years...if

only used to make eye drops.. But its not something a non-professional

should do.. and once made, the drops would not have a very long shelf life

at all, (just a few days, even in the refrigerator) because there would be

no preservatives in it along with the tiny amount of salt and distllled

water. Maybe a compounding pharmacist could hold on to your bottle of

carnosine and make small batches up for you on demand. Or know a good way to

preserve it so you could keep it longer. I wouldn't even want to try to

guess. Especially if you have had surgery, avoiding infections of any kind

is REALLY important. You could easily make a mistake - say, by contaminating

your 'creation' - that could HURT your eyes.

In fact, let me repeat that in bold letters..

DON'T TRY TO DO IT YOURSELF!!!! You only have one life and your eyesight is

precious..

On Sun, Aug 10, 2008 at 1:41 PM, who <jeaninem660@...> wrote:

> Thank you Live, I'll check this out. ,u left eye is full so I don't srr

> anyway around surgery, but stopping the process in the right eye would

> be great.

>

>

>

> >

> > Jeanine,

> >

> > L-carnosine (available OTC) and n-acetylcarnosine (patented,

> commercial

> > product)

> > have shown promise in topical application against cataracts.

> >

> > Don't try to make carnosine eye drops yourself. Show the l-carnosine

> papers

> > to a compounding pharmacist.

> >

>

>

[Guest guest]

lol's Live, I'm sick, not stupied.

> >

> > >

> > > Jeanine,

> > >

> > > L-carnosine (available OTC) and n-acetylcarnosine (patented,

> > commercial

> > > product)

> > > have shown promise in topical application against cataracts.

> > >

> > > Don't try to make carnosine eye drops yourself. Show the l-

carnosine

> > papers

> > > to a compounding pharmacist.

> > >

> >

> >

>

>

>

[Guest guest]

Live, no.1 I'm not a dog. no.2 do you actually think I would be dumb

enough to try that myself? I dont think I'd even put alot of faith in

someone else doing it. wuailfied or not. this is my eyes we are

talking about.

> >

> > >

> > > Jeanine,

> > >

> > > L-carnosine (available OTC) and n-acetylcarnosine (patented,

> > commercial

> > > product)

> > > have shown promise in topical application against cataracts.

> > >

> > > Don't try to make carnosine eye drops yourself. Show the l-

carnosine

> > papers

> > > to a compounding pharmacist.

> > >

> >

> >

>

>

>